A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ197) in Children with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study Phase 1 and Pilot Consortium Trial (ADVL1111)

BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase I and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tum...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Autores principales: Geller, James I., Perentesis, John P., Liu, Xiaowei, Minard, Charles G., Kudgus, Rachel A., Reid, Joel M., Fox, Elizabeth, Blaney, Susan M., Weigel, Brenda J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5657151/
https://ncbi.nlm.nih.gov/pubmed/28449393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26565
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares